nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-6F94AB06·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Pathology and Forensic Medicine·Basis: Full text·Type: Cross-sectional study

Neurofilament light chain and glial fibrillary acidic protein as biomarkers of peripheral nervous system involvement in multiple sclerosis: diagnostic and prognostic evaluation.

Flintere-Flinte et al.Flintere-Flinte, Krutovs, Pantelejeva et al.·2026·BMC neurology·10.1186/s12883-026-05024-y ↗

Primary claim

Serum NfL was found to be a reliable marker of disease activity and progression.

Tentative · cross-sectional comparisons cannot establish monitoring reliability or progression prediction
In brief

A useful cross-sectional biomarker study confirms higher NfL in MS, but unsupported diagnostic and prognostic framing obscures its limited PNP-specific advance.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Unlikely to hold — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

BACKGROUND: Multiple sclerosis is a chronic demyelinating disease of the central nervous system caused by an immune-mediated inflammatory process. Its aetiology remains unclear, and numerous pathogenetic theories have been proposed. The diversity of clinical manifestations and the lack of reliable biomarkers make diagnosis challenging. Serum neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) have been investigated as potential biomarkers for disease progression and response to disease-modifying therapies; however, their specificity and sensitivity remain variable, particularly in the presence of other conditions associated with neuronal damage and neurodegeneration.

METHODS: This retrospective study analysed serum NfL and GFAP levels in 149 patients with multiple sclerosis and 40 healthy controls. Additionally, the association between the two biomarkers was evaluated in patients with and without polyneuropathy to assess their reliability and prognostic value for disease severity and progression.

RESULTS: Serum NfL was found to be a reliable marker of disease activity and progression. In contrast, GFAP demonstrated limited specificity and was not suitable as a single, independent biomarker. The presence of co-existing polyneuropathy influenced biomarker levels and complicated their interpretation.

CONCLUSION: Serum NfL shows promise as a reliable biomarker for monitoring disease activity and progression in multiple sclerosis. However, GFAP should not be used independently due to its limited specificity. Co-existing polyneuropathy may further reduce the reliability of these biomarkers, highlighting potential diagnostic challenges in clinical practice.

Key Claims

Primary finding · Tentative

Serum NfL was found to be a reliable marker of disease activity and progression.

Unlikely to hold — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

cross-sectional comparisons cannot establish monitoring reliability or progression prediction

Abstract, Results
Quote verified
Secondary · Tentative

The presence of co-existing polyneuropathy influenced biomarker levels and complicated their interpretation.

the small cross-sectional PNP subgroup showed no independent adjusted NfL effect

Abstract, Results
Quote verified
Secondary · Tentative

GFAP demonstrated limited specificity and was not suitable as a single, independent biomarker.

group differences were tested, but diagnostic specificity and independent performance were not evaluated

Abstract, Results
Quote verified
Secondary · Supported

serum NfL levels were significantly higher in patients with MS compared to healthy controls

adjusted group comparisons support the direction despite baseline-reporting and cross-sectional limitations

Discussion, paragraph 3; Table 2
Quote verified
Secondary · Supported

differences between MS patients with and without PNP were attenuated after adjustment for age and sex

Table 2 directly reports near-elimination of the contrast after adjustment, though residual confounding remains

Discussion, paragraph 3; Table 2
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Standardised electrophysiological PNP classification

All patients underwent a standardised NCS protocol, and large-fibre PNP required abnormalities in multiple parameters across at least two nerves. This gives the subgroup comparison a clinically grounded phenotype.

↳ Methods, Clinical Assessment and Group Classification

#methodological rigour

Blinded single-batch biomarker measurement

NfL and GFAP were measured using Simoa in one batch by technicians blinded to clinical data, with intra-assay coefficients of variation below 10%.

↳ Methods, Blood Sampling and Biomarker Analysis

#positioning

Limitations linked to interpretation

The Discussion and Limitations address treatment confounding, absent age-adjusted Z-scores, mixed PNP aetiology, random sampling relative to relapse, and the need for an isolated-PNP comparator.

↳ Discussion, treatment paragraph; Limitations

Limitations

#methodological rigour

Baseline age statistics appear inconsistent

The MS-with-PNP group is approximately 10 years older than the MS-without-PNP group, yet the Results report p > 0.05. Because age is strongly associated with NfL in Table 2, this inconsistency bears directly on the central adjusted comparison.

↳ Results, paragraph 1; Table 2

#reporting

Abstract overstates clinical validation

The Abstract calls NfL reliable for activity and progression and attributes an effect to PNP, although the Introduction disclaims prognostic testing and the adjusted PNP comparison is p = 0.951.

↳ Abstract, Results and Conclusion; Introduction, final paragraph; Table 2

#contribution

Novel PNP comparison remains unresolved

Only 24 MS patients had PNP, and the adjusted difference from MS without PNP was 0.06 with p = 0.951. The study therefore does not demonstrate an independent PNP effect on NfL.

↳ Results, Table 2; Discussion, paragraph 3

Does this match your read? Add your assessment ↓

Nabu Commentary

The strongest result is the age- and sex-adjusted elevation of NfL in both MS groups relative to controls, while GFAP does not differ significantly across groups. The novel comparison between MS patients with and without PNP is much less informative because the PNP subgroup is small and its adjusted NfL contrast is essentially null. Standardised NCS classification, blinded Simoa measurement, and appropriate modelling support the exploratory analysis, but treatment, disease activity, selection, and PNP aetiology remain incompletely controlled. Scores are held in the 2.5–3.4 range because the Abstract's diagnostic and prognostic framing materially exceeds what the cross-sectional evidence and the paper's own Discussion permit.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.7±0.1

Contribution
2.6

The study adds a small NCS-defined cohort addressing whether PNP complicates NfL and GFAP interpretation in MS. Its principal MS-control finding is established, while the adjusted PNP comparison is null and leaves the novel question unresolved.

Results, Tables 1–2; Discussion, paragraphs 2–3

the lack of a robust independent effect limits definitive conclusions

Methodological Rigour
2.7

NCS-based PNP classification, blinded single-batch Simoa measurement, and age/sex-adjusted gamma modelling fit the cross-sectional association question. Selection procedures are thinly described, treatment and mixed PNP aetiology remain unresolved, and the baseline age comparison is internally questionable.

Methods, Study Population, Clinical Assessment, Biomarker Analysis and Statistical Analysis; Results, paragraph 1 and Table 2
Reporting
2.9

The body generally distinguishes cross-sectional associations from prognostic evidence. The title and Abstract nevertheless present diagnostic, monitoring, progression, specificity, and PNP-effect claims that exceed the analyses and conflict with the paper's own qualifications.

Title; Abstract, Results and Conclusion; Introduction, final paragraph; Discussion, final paragraphs

This study was not designed to evaluate diagnostic accuracy or prognostic prediction.

Positioning
2.8

The Discussion engages relevant biomarker, treatment, age-standardisation, and neuropathy literature and traces several limitations to interpretation. Positioning is capped because the Abstract asserts monitoring and progression value that the Discussion explicitly says cannot be concluded from this design.

Discussion, treatment and concluding paragraphs; Limitations; Abstract, Conclusion

direct conclusions regarding disease monitoring, progression, or treatment response cannot be drawn

Lower confidence on Contribution, Methodological Rigour — domain match limited.

Reliability

Caveats4 of 4 checks


Results checkNoted
  • The presence of co-existing polyneuropathy influenced biomarker levels and complicated their interpretation: "The presence of co-existing polyneuropathy influenced biomarker levels and complicated their interpretation." (Abstract, Results) vs "MS with PNP – MS without PNP0.06-1.91–2.440.951" (Table 2, model with covariates). Compare the Abstract's affirmative PNP-effect statement with the adjusted within-MS NfL contrast, which is 0.06 pg/mL with a 95% CI of −1.91 to 2.44 and p = 0.951; the Results also report no significant GFAP group differences. → Not supported by the paper's own data
  • differences between MS patients with and without PNP were attenuated after adjustment for age and sex: "The mean age was 41.5 ± 11.1 years in the control group, 50.3 ± 8.1 years in the MS with PNP group, and 40.6 ± 11.2 years in the MS without PNP group (p > 0.05)." (Results, first paragraph) vs "The sex distribution was as follows: control group (11 male, 29 female), MS with PNP group (13 male, 11 female), and MS without PNP group (41 male, 84 female)." (Results, first paragraph). Using group sizes 24 and 125 from the sex counts and treating the rounded age summaries as inputs, an assumed two-sided Welch comparison gives t ≈ 5.02, df ≈ 41.94 and p ≈ 0.00001, challenging baseline age comparability but not changing the separately reported adjusted PNP contrast. → Conclusion holds
Reporting and transparencyNoted

Correlation analyses described in Methods are not presented, leaving the conclusion's disability association uncheckable. The descriptive biomarker summaries also mix mean and median labels.

Conflict of interest: not stated · Ethics approval: declared · Preregistration: not stated · Data availability: not stated · Code availability: not stated

Reference IntegrityClean

22 references in manuscript 22 of 22 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Multiple sclerosis
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesSmall
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The evidence is a single-centre retrospective cross-sectional cohort showing group associations, with no longitudinal follow-up, diagnostic-accuracy testing, or independent validation of a monitoring role.

From the paper
“Serum NfL shows promise as a reliable biomarker for monitoring disease activity and progression in multiple sclerosis.”

The paper names a real-world use of its findings, serum NfL as a monitoring biomarker in MS, but does not clearly name who would act on them.

Pathway

Neurologists in MS clinics could use serum NfL to track disease activity, screening for polyneuropathy to aid interpretation.

Barrier

Its cross-sectional single-centre design, treatment and age confounding, and lack of validated reference thresholds prevent confident clinical biomarker use.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Kappa Free Light Chains Reflect Treatment Response and Progression Independent of Focal Inflammation in Multiple Sclerosis

    Rosenstein, Axelsson, Johnsson, et al. · 2026 · Clinical medicine

    Primary claim

    Natalizumab appears to reduce intrathecal KFLC synthesis, and a decline in KFLC index may reflect effective suppression of CNS humoral immunity.

    Supported
    Evidence Score
    3.0±0.2
    Reliability
    Caveats
  2. A novel multiplexed biomarker panel reveals key molecular pathways in progressive multiple sclerosis

    Heiss, Novakova, Axelsson, et al. · 2026 · Clinical medicine

    Primary claim

    Among RRMS patients, low baseline CSF concentrations of KIT ligand (KITLG) predicted both conversion to SPMS and future PIRMA events.

    Tentative
    Evidence Score
    2.5±0.2
    Reliability
    Caveats
  3. DNA damage burden causes selective CUX2 neuron loss in neuroinflammation

    Morcom, Xia, Xu, et al. · 2026 · Basic medicine

    Primary claim

    These findings indicate that DNA damage burden and inadequate repair in CUX2+ L2/3ENs contributes to selective vulnerability in neuroinflammatory injury.

    Supported
    Evidence Score
    3.1±0.1
    Reliability
    No concerns

How the rubric works →